title: [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)].
authors.forename: M
authors.initials: M
authors.lastname: Barthet
authors.forename: P
authors.initials: P
authors.lastname: Brunet
authors.forename: J C
authors.initials: JC
authors.lastname: Bernard
authors.forename: B
authors.initials: B
authors.lastname: Dussol
authors.forename: F
authors.initials: F
authors.lastname: Rodor
authors.forename: J
authors.initials: J
authors.lastname: Jouglard
authors.forename: Y
authors.initials: Y
authors.lastname: Berland
authors.forename: J
authors.initials: J
authors.lastname: Sahel
mesh_terms: D000208:Acute Disease; D000328:Adult; D000818:Animals; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007893:Leishmania donovani / Q000302:isolation & purification; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000382:microbiology; D008536:Meglumine / Q000009:adverse effects* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced*
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate
vernacular_title: Pancréatite aiguë au cours d'un traitement par l'antimoniate de méglumine (Glucantime).